The novel role of TRPC6 in vitamin D ameliorating podocyte injury in STZ-induced diabetic rats

Molecular and Cellular Biochemistry

Volumn 399, Issue 1-2, 2015, Pages 155-165

  Zhang, Xiaoliang ^a   Song, Zhixia ^a   Guo, Yinfeng ^a   Zhou, Min ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Calcitriol; Diabetic nephropathy; Podocyte; TRPC6; Vitamin D receptor

Indexed keywords

CALCITRIOL; CALCIUM; CREATININE; DESMIN; GLUCOSE; NEPHRIN; PHOSPHORUS; PODOCIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; STREPTOZOCIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, RAT; WT1 PROTEIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CELL DAMAGE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; NONHUMAN; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PODOCYTE; PODOCYTE INJURY; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ALBUMINURIA; ANIMALS; CALCITRIOL; DESMIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY; MALE; PODOCYTES; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; STREPTOZOCIN; TRPC CATION CHANNELS; WT1 PROTEINS;

EID: 84916897362     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2242-9     Document Type: Article

References (48)

1. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310:948–959
2. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK (2008) The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol Hypertens 17:32–36
3. Kumar PA, Brosius FC, Menon RK (2011) The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy. Curr Diabetes Rev 7:50–55
4. 2+ signaling: evidence from NOD2-regulated podocyte TRPC6 channels in hyperhomocysteinemia. Hypertension 62:506–511
5. Dryer SE, Reiser J (2010) TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. Am J Physiol Renal Physiol 299:F689–F701
6. Liu BC, Song X, Lu XY, Li DT, Eaton DC, Shen BZ, Li XQ, Ma HP (2013) High glucose induces podocyte apoptosis by stimulating TRPC6 via elevation of reactive oxygen species. Biochim Biophys Acta 1833:1434–1442
7. Li Z, Xu J, Xu P, Liu S, Yang Z (2013) Wnt/beta-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif 46:76–85
8. Fornoni A (2010) Proteinuria, the podocyte, and insulin resistance. N Engl J Med 363:2068–2069
9. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR (2005) TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37:739–744
10. Eckel J, Lavin PJ, Finch EA, Mukerji N, Burch J, Gbadegesin R, Wu G, Bowling B, Byrd A, Hall G, Sparks M, Zhang ZS, Homstad A, Barisoni L, Birbaumer L, Rosenberg P, Winn MP (2011) TRPC6 enhances angiotensin II-induced albuminuria. J Am Soc Nephrol 22:526–535
11. Kim EY, Anderson M, Dryer SE (2012) Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen species. Am J Physiol Renal Physiol 302:F298–F307
12. Liu D, Zhu Z, Tepel M (2008) The role of transient receptor potential channels in metabolic syndrome. Hypertens Res 31:1989–1995
13. +) influx is mediated by the 1/4/5 subgroup of the transient receptor potential proteins in cultured aortic smooth muscle cells from diabetic Goto-Kakizaki rats. Mol Cell Endocrinol 302:49–57
14. Woudenberg-Vrenken TE, Bindels RJ, Hoenderop JG (2009) The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol 5:441–449
15. Graham S, Gorin Y, Abboud HE, Ding M, Lee DY, Shi H, Ding Y, Ma R (2011) Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes. Am J Physiol Cell Physiol 301:C304–C315
16. Moller CC, Flesche J, Reiser J (2009) Sensitizing the slit diaphragm with TRPC6 ion channels. J Am Soc Nephrol 20:950–953
17. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB (2005) A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308:1801–1804
18. Moller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J (2007) Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18:29–36
19. Sonneveld R, Ferre S, Hoenderop JG, Dijkman HB, Berden JH, Bindels RJ, Wetzels JF, van der Vlag J, Nijenhuis T (2013) Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease. Am J Pathol 182:1196–1204
20. Wang Y, Deb DK, Zhang Z, Sun T, Liu W, Yoon D, Kong J, Chen Y, Chang A, Li YC (2012) Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol 23:1977–1986
21. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W Jr, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R (2012) Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 18:396–404
22. Pan MM, Zhang MH, Ni HF, Chen JF, Xu M, Phillips AO, Liu BC (2013) Inhibition of TGF-beta1/Smad signal pathway is involved in the effect of Cordyceps sinensis against renal fibrosis in 5/6 nephrectomy rats. Food Chem Toxicol 58:487–494
23. Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC (2003) Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms’ tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 14:2484–2493
24. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A (2002) WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 11:651–659
25. Jefferson JA, Shankland SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74:22–36
26. Tan AL, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130–143
27. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M (2008) Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 29:726–776
28. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281
29. Al-Badr W, Martin KJ (2008) Vitamin D and kidney disease. Clin J Am Soc Nephrol 3:1555–1560
30. Jones G (2007) Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 20:316–324
31. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456
32. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543–1551
33. Fernandez-Juarez G, Luno J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J (2013) 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin–angiotensin system. Clin J Am Soc Nephrol 8:1870–1876
34. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E (2007) Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18:1796–1806
35. He W, Kang YS, Dai C, Liu Y (2011) Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 22:90–103
36. Kiekhaefer CM, Weber B, Huggins M, Gorichanaz C, Nehring JA, DeLuca HF (2011) 2alpha-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D(3) protects the insulin 2 knockout non-obese diabetic mouse from developing type 1 diabetes without hypercalcaemia. Clin Exp Immunol 166:325–332
37. Goel M, Sinkins WG, Zuo CD, Estacion M, Schilling WP (2006) Identification and localization of TRPC channels in the rat kidney. Am J Physiol Renal Physiol 290:F1241–F1252
38. Hsu YJ, Hoenderop JG, Bindels RJ (2007) TRP channels in kidney disease. Biochim Biophys Acta 1772:928–936
39. Huber TB, Schermer B, Benzing T (2007) Podocin organizes ion channel-lipid supercomplexes: implications for mechanosensation at the slit diaphragm. Nephron Exp Nephrol 106:e27–e31
40. Schlondorff J, Del Camino D, Carrasquillo R, Lacey V, Pollak MR (2009) TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol 296:C558–C569
41. Chiluiza D, Krishna S, Schumacher VA, Schlondorff J (2013) Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2). J Biol Chem 288:18407–18420
42. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931–938
43. Wang Y, Ding M, Chaudhari S, Ding Y, Yuan J, Stankowska D, He S, Krishnamoorthy R, Cunningham JT, Ma R (2013) Nuclear factor kappaB mediates suppression of canonical transient receptor potential 6 expression by reactive oxygen species and protein kinase C in kidney cells. J Biol Chem 288:12852–12865
44. Anderson M, Roshanravan H, Khine J, Dryer SE (2014) Angiotensin II activation of TRPC6 channels in rat podocytes requires generation of reactive oxygen species. J Cell Physiol 229:434–442
45. Thilo F, Lee M, Xia S, Zakrzewicz A, Tepel M (2014) High glucose modifies transient receptor potential canonical type 6 channels via increased oxidative stress and syndecan-4 in human podocytes. Biochem Biophys Res Commun 450:312–317
46. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of renin–angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394–1402
47. Xiao H, Shi W, Liu S, Wang W, Zhang B, Zhang Y, Xu L, Liang X, Liang Y (2009) 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 30:34–43
48. Haussler MR, Jurutka PW, Mizwicki M, Norman AW (2011) Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2) vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 25:543–559